From Berry to Bedside: Translational Potential of Berry-Derived Phytochemicals in HNSCC
Molecules · 02.06.2026 · 31 (11) · 1914
DOI: 10.3390/molecules31111914 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 02.06.2026. Verfasst von Kishan Kumar Nyati und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Pelotonia Institute for Immuno-Oncology, College of Medicine, The Ohio State University Wexner Medical Center, Columbus 4320…. Hauptthemen laut MEDLINE: Phytochemicals, Fruit, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms. Die Arbeit nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, U.S. National Institute of Health.
Abstract (Originalsprache)
Head and neck squamous cell carcinoma (HNSCC) remains an immunosuppressive and metabolically dysregulated malignancy, contributing to tumor progression and resistance to conventional therapies. Natural compounds offer a unique multi-target opportunity to address these challenges, with berry-derived phytochemicals emerging as particularly promising candidates. Preclinical evidence demonstrates that these compounds modulate dendritic cell activation, macrophage polarization, regulatory T cell function, and cytokine signaling, restoring immune balance while simultaneously regulating tumor metabolism and reducing chronic inflammation. Beyond these immunometabolic effects, berry-derived compounds influence glucocorticoid signaling at the endocrine–immune interface, alleviating additional immunosuppressive pressures within the tumor microenvironment. Early clinical studies support the feasibility of standardized berry-derived formulations as adjunctive agents. In patients with oral premalignant lesions and HNSCC, black-raspberry-based interventions including topical gels and oral troches, have demonstrated favorable safety profiles, measurable tissue uptake of bioactive phytochemicals, modulation of proliferation and inflammation-associated biomarkers (e.g., Ki-67, COX-2, and NF-κB), and partial histologic regression in a subset of lesions. Collectively, these pleiotropic actions highlight chemopreventive potential and provide a mechanistic rationale for combinatorial strategies with immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4. Opportunities for both local and systemic delivery may further enhance therapeutic efficacy. Integrating these natural compounds into precision chemoprevention and immunotherapy paradigms could inform rational drug discovery, biomarker-driven patient stratification, and combination therapy design. This review highlights the convergent immunologic, metabolic, and endocrine-targeted mechanisms of berry-derived phytochemicals in HNSCC and emphasizes their translational potential as integrative modulators of antitumor immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Pelotonia Institute for Immuno-Oncology, College of Medicine, The Ohio State University Wexner Medical Center, Columbus 43201, OH, USA.
ORCID-Profile: Ravi Ramalingam, Sonali Dasari, Shaheer Masood, Steve Oghumu
Förderung
- NIH HHS
- U.S. National Institute of Health
Zitieren
APA
Nyati, K. K., Ramalingam, R., Shrestha, S., Jagadeesha, S., Dasari, S., Masood, S., Yade, M., Mehta, P. A., Kundety, S., & Oghumu, S. (2026). From Berry to Bedside: Translational Potential of Berry-Derived Phytochemicals in HNSCC. Molecules, 31(11), 1914. https://doi.org/10.3390/molecules31111914
Vancouver
Nyati KK, Ramalingam R, Shrestha S, Jagadeesha S, Dasari S, Masood S, et al. From Berry to Bedside: Translational Potential of Berry-Derived Phytochemicals in HNSCC. Molecules. 2026;31(11):1914. doi:10.3390/molecules31111914
BibTeX
@article{Nyati2026,
author = {Nyati, Kishan Kumar and Ramalingam, Ravi and Shrestha, Suvekshya and Jagadeesha, Sushmitha and Dasari, Sonali and Masood, Shaheer and Yade, Massar and Mehta, Parth A and Kundety, Shravya and Oghumu, Steve},
title = {From Berry to Bedside: Translational Potential of Berry-Derived Phytochemicals in HNSCC},
journal = {Molecules},
year = {2026},
volume = {31},
number = {11},
pages = {1914},
doi = {10.3390/molecules31111914}
}
EUVIMED